Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

Core Insights - Akeso's partner, Summit Therapeutics, has entered a clinical trial collaboration with Pfizer to evaluate ivonescimab, a novel PD-1/VEGF bispecific antibody, in combination with Pfizer's antibody drug conjugates across multiple solid tumor settings [1][2][3] Company Overview - Akeso is a leading biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative biological medicines, founded in 2012 [5] - The company has developed a comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) [5] - Akeso has a robust pipeline of over 50 innovative assets, with 23 candidates currently in clinical trials, including 11 bispecific/multispecific antibodies and bispecific antibody-drug conjugates [5] Product Information - Ivonescimab, also known as SMT112 in Summit Therapeutics's territories, is a first-in-class PD-1/VEGF bispecific immunotherapy drug approved by NMPA for treating EGFR mutated locally advanced or metastatic non-squamous NSCLC patients [4] - The drug is currently undergoing 6 registrational trials against anti-PD-1/L1 therapeutics and is being tested for 17 indications, including gastrointestinal cancer, hepatocellular carcinoma, and colorectal cancer [4]